OT-82, a preclinical stage drug candidate developed at Roswell Park Comprehensive Cancer Center (RPCCC) Buffalo, shows promise as a treatment to fight high-risk leukemia. Licensed for R&D and commercialization to OncoTartis, a biotech venture organized by RPCCC’s...